Clinical trial
Optimal Survival and Quality of Life in Patients With Metastatic Colorectal Cancer With Irinotecan Dosing Based on UGT1A1 Genotype and Gut Microbiota Enzyme Activity Including a Dietary Intervention (OPTIMA)
NCT05655780 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Optimal Survival and Quality of Life in Patients With Metastatic Colorectal Cancer With Irinotecan Dosing Based on UGT1A1 Genotype and Gut Microbiota Enzyme Activity Including a Dietary Intervention (OPTIMA)
- Lead sponsor
- Maastricht University Medical Center
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 9, 2023
- Completion date
- December 31, 2028
- Enrollment
- 104 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.